Cambridge-based genomics company OutSee has raised £1.8 million (US$2.3 million) in seed funding.

The funding round was led by Ahren Innovation Capital, with participation from Kadmos Capital, Empirical Ventures, and Panacea Ventures.

OutSee specializes in drug discovery using its AI-based Nomaly technology.

This technology predicts diseases and phenotypes from a single genome through predictive modeling, rather than traditional pattern-matching methods.

The newly secured funds will support OutSee’s in-house target discovery program and establish partnerships with pharmaceutical and biotech companies.

🔗 Source: Tech EU

🧠 Food for thought

1️⃣ AI-genomics startups entering a rapidly expanding market

OutSee’s £1.8 million seed funding comes at a time when the AI drug discovery market is experiencing exponential growth, projected to expand from $1.72 billion in 2024 to $8.53 billion by 2030, reflecting a 30.59% compound annual growth rate 1.

This investment momentum is part of a broader industry shift where genomics is expected to play a significant role in the drug discovery platforms market, contributing 23.5% of the market share in 2025 2.

Investors like Ahren Innovation Capital are focusing on platforms that can extract novel insights from genomic data, recognizing that AI-enhanced genomic analysis has the potential to improve the traditionally low success rates in drug development.

The funding landscape reflects growing confidence in AI’s ability to transform pharmaceutical R&D, with numerous strategic partnerships forming between AI startups and established pharmaceutical companies to leverage these technologies 3.

2️⃣ Extracting insights from limited datasets addresses a critical industry gap

OutSee’s claim that Nomaly can generate valuable insights from small datasets addresses a significant challenge in genomics research, particularly for rare diseases where large patient cohorts are unavailable.

Despite advances in sequencing technology that have dramatically reduced costs, the pharmaceutical industry still struggles with data quality and integration challenges, with AstraZeneca emphasizing the need to make genomic data “FAIR” (findable, accessible, interoperable, reusable) 4.

The ability to reanalyze previously studied data is especially valuable as the human genome consists of over 20,000 genes and 3 billion base pairs, with traditional analysis methods often missing subtle patterns that AI can detect 5.